Welcome to our dedicated page for Stevanato Group S P A news (Ticker: STVN), a resource for investors and traders seeking the latest updates and insights on Stevanato Group S P A stock.
Stevanato Group S.P.A. (STVN) delivers critical solutions for pharmaceutical containment, drug development, and diagnostic systems. This page provides a centralized resource for tracking the company's official communications and market developments.
Access comprehensive updates including earnings announcements, manufacturing innovations, and strategic partnerships. Stay informed about advancements in glass primary packaging, automated inspection systems, and regulatory milestones impacting the biopharma supply chain.
Our curated news collection serves investors and industry professionals seeking to monitor STVN's dual-division operations across pharmaceutical systems and engineering solutions. Content spans product launches, quality control initiatives, and capacity expansions critical to parenteral medicine production.
Bookmark this page for streamlined access to verified updates about Stevanato Group's role in global healthcare infrastructure. Check regularly for developments in drug delivery technologies and engineering advancements shaping pharmaceutical manufacturing.
Stevanato Group (NYSE: STVN), a leading global provider of drug containment, delivery, and diagnostic solutions, will participate in two upcoming investor conferences. These events are the William Blair Growth Stock Conference in Chicago on June 4, 2024, at 4:00 p.m. (CT), and the Jefferies Healthcare Conference in New York City on June 6, 2024, at 9:30 a.m. (ET). Live webcasts will be available on the Stevanato Group's website under the 'Investors' section, with replays accessible for approximately 90 days post-event.
Stevanato Group S.p.A. reported financial results for Q1 2024, with revenue decreasing by 1% to €236.0 million. The company adjusted its fiscal year 2024 guidance due to industry destocking and postponed orders, expecting revenue between €1,125 million to €1,155 million. Despite challenges, the company remains confident in its strong fundamentals and growth potential in biologics. The BDS segment revenue grew by 2% to €198.9 million, while the Engineering segment revenue decreased by 13% to €37.1 million. The company raised net proceeds of €170.5 million in a public offering, maintaining mid-term targets for fiscal years 2025 to 2027.
Stevanato Group, a global leader in drug containment, drug delivery, and diagnostic solutions, will participate in the Bank of America Securities Healthcare Conference from May 14 to May 16, 2024. The Company will present on May 15, 2024, at 11:20 a.m. (PT). A live webcast will be accessible on the Company's website, with a replay available for 90 days.
FAQ
What is the current stock price of Stevanato Group S P A (STVN)?
What is the market cap of Stevanato Group S P A (STVN)?
